II. Epidemiology
- Incidence: 1.1 in 100,000
III. Risk Factors
- No predisposing factors (other than Otitis Externa) in 20% of cases
- Water exposure
- Associated with the initial Otitis Externa risk
-
Diabetes Mellitus (90% of cases)
- Microangiopathy, impaired Wound Healing, increased cerumen pH allow for Bacterial growth
- Elderly
- Risk increases with age (very rare in children)
- Elderly are at higher risk of complications including higher mortality
-
Immunocompromised state
- Chemotherapy
- Hematologic Malignancy
- Status post organ transplant
- Chronic Kidney Disease
- Human Immunodeficiency Virus (HIV, AIDS)
IV. Causes
-
Bacteria
- See Bacterial Otitis Externa
- Pseudomonas Aeruginosa (50-90% of cases)
- Proteus
- Klebsiella
- Staphylococcus (including MRSA)
-
Fungi (esp. male, Diabetes Mellitus)
- See Fungal Otitis Externa
- Aspergillus
- Candida
V. Pathophysiology
- Triad allows for Malignant Otitis Externa
- Epidermal disruption
- Immunocompromised state
- Otitis Externa infection
- Necrotizing infection of the soft tissue of the external auditory canal
- Infection invades Temporal Bone and skull base
- Pseudomonas Aeruginosa is most common causative organism (accounts for 95% of cases)
- Staphylococcus Aureus accounts for the remaining cases
- Skull Base Osteomyelitis is a complication of Otitis Externa
- Infection extends into ear canal cartilage and ultimately into Temporal Bone
- Temporal Bone surrounds the inner two thirds of the ear canal (outer third is cartilage)
- Fissures of santorini in the cartilage may allow Otitis Externa to spread to deeper structures
- Severe extension of external Otitis Media
- Mastoiditis
- Osteitis of Temporal Bone
VI. Symptoms: Severe Otitis Externa
- Severe, unrelenting Ear Pain and Headache
- Often progressing over 1 to 2 weeks
- Contrast with typical Otitis Externa in which symptoms are more mild
- Persistent discharge
- Hearing Loss
- Does not respond to Topical Medications
- Commonly associated with Diabetes Mellitus
- Fever is typically absent
VII. Signs
- Purulent Otorrhea
- Tender and swollen external auditory canal
- Tympanic Membrane spared
- Granulation tissue in posterior and inferior canal and possible exposed Temporal Bone
- Pathognomonic for necrotizing otitis
- Occurs at bone-cartilage junction
- Extra-auricular findings
- Cervical Lymphadenopathy
- Parotitis
- TMJ Involvement
- Trismus
- Preauricular tenderness
- Pain worse with chewing
- Facial Nerve Palsy or paralysis (Bell's Palsy)
- Facial Nerve Paralysis is most common Cranial Nerve Involvement (20% of malignant otitis cases)
- Suggests infection an inflammation at the Temporal Bone's stylomastoid foramen
- Other Cranial Nerves
- Other Cranial Nerves may be affected with infection of the skull base and jugular foramen
- Cranial Nerve Involvement indicates significant progression and associated with increased morbidity and mortality
- Intracranial spread (neurologic findings specific to involvement)
- Intracranial Abscess
- Otogenic Meningitis
- Jugular vein Thrombophlebitis
- Cerebral Venous Sinus Thrombosis
VIII. Labs
-
Complete Blood Count
- Often normal in Malignant Otitis Externa
- Chemistry panel
- Culture ear discharge (obtain in all cases of suspected Malignant Otitis Externa)
- Bacterial cultures
- Fungal Cultures
- Histology of granulation tissue excised from canal
-
C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR)
- Often markedly elevated and may be used to track progression
- May be unreliable in Immunocompromised patients
- C-Reactive Protein (CRP) >10 mg/L (LR+ 8)
- Erythrocyte Sedimentation Rate (ESR) >26 mm/h (LR+ 10)
- Elevated in nearly 70% of patients (mean 65 mm/h)
IX. Imaging
- High Resolution CT Scan of Temporal Bone (and consider CT Brain with contrast)
- CT is best for bony involvement (e.g. erosions) evaluation and more readily available than other imaging
- CT findings lag behind clinical findings and may miss early cases
- Test Sensitivity for bony erosions 48%
- Test Sensitivity for early findings (canal thickening, fat stranding, contrast enhancement): 95%
- CT may also demonstrate abscess formation
- Ear MRI with contrast
- CT or MR Venogram
- Consider for evaluation of dural venous sinus thrombosis (NOE complication)
- Nuclear imaging
- Technetium Tc 99m medronate methylene bone scanning
- Gallium citrate Ga 67 scintography
- High sensitivity for current infection
- Useful for follow-up for resolution
X. Differential Diagnosis
- See Otalgia
- Otitis Media
- Otitis Externa
- Mastoiditis
- Malignancy
- Cholesteatoma
XI. Staging
- Stage 1
- Severe local Otalgia with granulation tissue
- Stage 2
- Limited Skull Base Osteomyelitis
- Facial Nerve Palsy
- Stage 3
- Severe, extensive temporal and Skull Base Osteomyelitis with bony erosions
- Multiple Cranial Nerve Involvement (CN 7, CN 9, CN 10, CN 11)
XII. Precautions
- Typical patient is an elderly, diabetic man with 1-2 weeks of progressive Ear Pain
- Malignant Otitis Externa is an easily missed diagnosis early in course
- Difficult to distinguish from Acute Otitis Externa
- Delayed diagnosis is associated with increased morbidity and mortality
XIII. Management
- Admit most patients to hospital
- Cranial Nerve Involvement
- Septic thrombosis
- Cerebral Venous Sinus Thrombosis
- Intracranial Abscess
- Meningitis
- Comorbid Diabetes Mellitus (for optimal Glucose control)
- Consult Otolaryngology (ENT) early
- Surgical Debridement may rarely be required
- Close follow-up with ENT is also needed for the first year (high Antibiotic failure and recurrence rate)
-
Anti-Pseudomonal Antibiotics
- Pseudomonas is the most causative Bacteria (esp. in Diabetes Mellitus)
- Intravenous Antibiotic options (adult dosing is listed)
- Ciprofloxacin 400 mg IV every 8 hours (preferred)
- Combine with beta-lactam broad coverage (agents below) in septic patients
- Imipenem 0.5 mg IV q6 hours
- Imipenem is preferred in children
- Meropenem 1.0 grams IV q8 hours
- Ceftazidime 2.0 grams IV q8 hours
- Cefepime 2.0 grams IV q12 hours
- Piperacillin-Tazobactam 4.5 g IV every 6-8 hours AND Aminoglycoside (Tobramycin or Gentamicin)
- Ciprofloxacin 400 mg IV every 8 hours (preferred)
- Other coverage to consider
- MRSA coverage (e.g. Vancomycin) in those with abscess or MRSA history
- MRSA is also more common in non-diabetic patients
- MRSA is associated with a worse prognosis
- Antifungal (e.g. Voriconazole, Liposomal Amphotericin B) Indications
- Consider empirically (or after culture) in HIV Infection, Diabetes Mellitus or transplant history
- Fungi have increased morbidity/mortality, delayed diagnosis, extensive spread, Cranial Nerve Involvement
- Voriconazole is preferred
- Cover Aspergillus and candida
- Consult infectious disease
- Oral Antibiotic options (after initial IV course or for mild, early involvement)
- Ciprofloxacin 750 mg orally every 12 hours
- Course
- Start with IV Antibiotics
- Continue Antibiotics for 6 to 8 weeks if bone involvement (shorter courses if not)
- Alternative course in a well appearing reliable patient
- Ceftazidime can be given IM and could be used with follow-up within 8-12 hours
- Hospital admission with IV Antibiotics is safest course
- Clean ear canals meticulously on a daily basis
- Clean and debride canal
- Topical Antibiotic agent use is controversial
- Topicals do not add value in NOE once systemic Antibiotics are initiated
- May alter culture results and not needed in aggressive intravenous Antibiotic management
- However, in borderline cases, where diagnosis is initially unclear, may continue during evaluation
- Other modalities to consider
- Hyperbaric oxygen chamber
- May offer benefit, but no strong evidence to support use
- Byun (2020) World J Otorhinolaryngol Head Neck Surg 7(4):296-302 +PMID: 34632343 [PubMed]
- Davis (1992) Arch Otolaryngol Head Neck Surg 118:89 [PubMed]
- Hyperbaric oxygen chamber
XIV. Complications
- Skull Osteomyelitis
-
Cranial Nerve palsy
- Facial Nerve Palsy (CN 7) is most common
- With spread of infection toward jugular foramen at skull base, CN 9, CN 10 and CN 11 may become involved
- Septic Cerebral Venous Sinus Thrombosis
- Meningitis
- Cerebral Abscess
XV. Prognosis
- Untreated mortality reportedly as high as 20 to 53%
- One year mortality: 2-4%
- Treatment failure 22%
- Recurrence within 1 year: 7%
XVI. Prevention
XVII. References
- (2019) Sanford Guide, accessed on IOS, 11/28/2019
- Bardakos, Raj and Mehta (2026) Crit Dec Emerg Med 40(2): 4-12
- Khoujah (2013) Crit Dec Emerg Med 27(4): 12-21
- Werner and Long (2023) EM:Rap, accessed 7/2/2023
- Bath (1998) J Laryngol Otol 112:274-7 [PubMed]
- Handzel (2003) Am Fam Physician 68(2):309-12 [PubMed]
- Sander (2001) Am Fam Physician 63:927-42 [PubMed]
- Selesnick (1994) Am J Otol 15:408-12 [PubMed]
- Takata (2023) Clin Otolaryngol 48(3): 381-94 [PubMed]
- Vaca (2024) Eur Arch Otorhinolaryngol 281(2): 737-42 [PubMed]